Gilead Sciences Inc. (NASDAQ:GILD) had its price target cut by Credit Suisse Group AG from $115.00 to $95.00 in a research report report published on Wednesday. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. Jefferies Group cut their price target on Gilead Sciences from $93.00 to $91.00 and set a hold rating on the stock in a report on Wednesday, August 31st. Piper Jaffray Cos. reissued an overweight rating and issued a $108.00 price target on shares of Gilead Sciences in a report on Wednesday, August 31st. Vetr raised Gilead Sciences from a buy rating to a strong-buy rating and set a $93.97 price target on the stock in a report on Tuesday, July 26th. S&P Equity Research reissued a strong-buy rating on shares of Gilead Sciences in a report on Wednesday, July 27th. Finally, Morgan Stanley set a $100.00 price target on Gilead Sciences and gave the stock a hold rating in a report on Tuesday, September 6th. Nine investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $105.41.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 78.80 on Wednesday. The stock has a market capitalization of $103.99 billion, a P/E ratio of 6.92 and a beta of 1.06. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $113.31. The firm’s 50-day moving average price is $79.54 and its 200-day moving average price is $86.33.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter last year, the business posted $3.15 EPS. Gilead Sciences’s quarterly revenue was down 5.7% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences will post $11.77 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.39%. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.

In other Gilead Sciences news, Chairman John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the transaction, the chairman now directly owns 4,119,727 shares in the company, valued at $349,064,468.71. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total value of $9,444,960.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Van Hulzen Asset Management LLC raised its position in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Joel Isaacson & Co. LLC raised its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Roble Belko & Company Inc raised its position in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the period. Pinkerton Retirement Specialists LLC raised its position in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the period. Finally, Jolley Asset Management LLC raised its position in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares during the period. Institutional investors own 77.96% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.